 SAN DIEGO, Feb. 22, 2021 GLOBE NEWSWIRE -- Adamis Pharmaceuticals Corporation Nasdaq: ADMP Company announced today that the U.S. Food and Drug Administration FDA has completed the safety review of the Companys Investigational New Drug IND application and has concluded that Adamis may proceed with the proposed clinical investigation of Tempol for the treatment of COVID-19. The clearance to proceed follows the submission of an IND application to FDA and a Pre-IND meeting. 